Yayın:
Efficacy and Safety of 400 and 800 mg Etodolac vs. 1,000 mg Paracetamol in Acute Treatment of Migraine: A Randomized, Double‐blind, Crossover, Multicenter, Phase III Clinical Trial

Sadeleştirilmiş öğe sayfası
dc.contributor.authorErtaş, Mustafa
dc.contributor.authorMustafa Ertaş
dc.contributor.authorBetül Baykan
dc.contributor.authorHadiye Şirin
dc.contributor.authorAynur Özge
dc.contributor.orcid0000-0001-9652-384X
dc.contributor.orcid0000-0003-0606-952X
dc.contributor.orcid0000-0002-3360-659X
dc.contributor.orcid0000-0003-2797-2398
dc.date.accessioned2025-11-13T10:23:05Z
dc.date.issued2012-06-25
dc.identifier.doihttps://doi.org/10.1111/j.1533-2500.2012.00572.x
dc.identifier.endpage197
dc.identifier.issn1530-7085
dc.identifier.issue3
dc.identifier.openalexW1492423759
dc.identifier.startpage191
dc.identifier.urihttps://hdl.handle.net/11421/3985
dc.identifier.urihttps://doi.org/10.1111/j.1533-2500.2012.00572.x
dc.identifier.volume13
dc.language.isoen
dc.relation.ispartofPain Practice
dc.rightsrestrictedAccess
dc.subjectMedicine
dc.subjectCrossover study
dc.subjectEtodolac
dc.subjectMigraine
dc.subjectDouble blind
dc.subjectClinical trial
dc.subjectAnesthesia
dc.subjectRandomized controlled trial
dc.subjectMulticenter study
dc.subjectSurgery
dc.subjectPharmacology
dc.subjectInternal medicine
dc.subjectPlacebo
dc.subjectAlternative medicine
dc.subject.sdg3
dc.titleEfficacy and Safety of 400 and 800 mg Etodolac vs. 1,000 mg Paracetamol in Acute Treatment of Migraine: A Randomized, Double‐blind, Crossover, Multicenter, Phase III Clinical Trial
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5039139738

Dosyalar

Koleksiyonlar

Publications